-- First patient treated at Velindre Cancer Centre, Wales (UK) --
Oxford, UK – 7 March 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that its partners at the Velindre Cancer Centre, one of the largest cancer centres in the UK, have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in combination with first-line chemotherapy agents pemetrexed and cisplatin in patients with malignant pleural mesothelioma. The study will be funded by the June Hancock Mesothelioma Research Fund (JHMRF) and the Velindre Cancer Centre Stepping Stones Appeal, and Oxford BioMedica will provide TroVax®.
The Phase II study, entitled “SKOPOS”, will be led by Dr Jason Lester at Velindre Cancer Centre in Cardiff, Wales, with Dr Zsuzsanna Tabi as Co-Investigator, and will enrol 26 patients with malignant pleural mesothelioma (MPM). The study will evaluate whether TroVax® is active in the treatment of MPM, assessed by measuring anti-5T4 immune responses following treatment in combination with pemetrexed and cisplatin. The study will also assess secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival at six and 12 months.
TroVax® is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours. Dr Zsuzsanna Tabi at Cardiff University and a team of cancer immunologists previously undertook a feasibility project, also funded by the JHMRF, where the 5T4 tumour antigen was shown to be present on mesothelioma cells. Mesothelioma is a relatively rare form of cancer which affects the tissue lining of the lungs (the pleura) and, less commonly, the lining of the abdomen (the peritoneum). The disease can take 10-50 years or longer to develop and is usually associated with asbestos exposure. It is estimated that every five hours someone dies from mesothelioma in the UK and the annual number of deaths is expected to remain above 1,500 until 2025 (source: JHMRF).
Commenting on the collaboration, John Dawson, Chief Executive Officer of Oxford BioMedica, said: “This study is the first to evaluate TroVax® as a treatment for mesothelioma in the UK and we are privileged to be working with the immunology team at Velindre Cancer Centre. TroVax® has been shown to be effective at inducing immune responses in multiple types of cancer and, with few treatment options available for mesothelioma, could hold significant promise against this increasingly prevalent form of cancer.”
Dr Jason Lester, Chief Investigator at Velindre Cancer Centre, commented: “I am delighted that the SKOPOS study is now open. Mesothelioma is one of the hardest cancers to treat and can be very debilitating for patients. We are hopeful that TroVax® in combination with chemotherapy will show promise and lead to better outcomes for patients with mesothelioma.”
Dr Kate Hill, trustee of the June Hancock Mesothelioma Research Fund, said:“Given the limited options available for the treatment of mesothelioma, the Fund is thrilled to support the SKOPOS study. We are also delighted to continue our association with the Velindre Cancer Centre and enable the valuable laboratory work previously funded by the June Hancock Mesothelioma Research Fund to move on to the next stage. There is no doubt that new approaches to treating mesothelioma are needed; this study is an important step forward.”
- Ends -
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321